![Figure 1. Identification of AML-specific antibodies. (A) Antibodies in the supernatant of 1 of the minicultures (11C9; 40 cells per well) binding to the AML cell line THP-1 (top panels). B cells from this miniculture were plated into 1 cell per well solutions and supernatants again screened for antibodies binding to THP-1 (lower panels). Positive control: HLA antigen D related (HLA-DR); negative control: in-house generated, influenza-specific antibody AT1002.12 Recombinant-produced 11C9-22C11 was named AT1223. FSC, free secretory component. (B) Representative example of binding of 3 of the selected antibodies (AT1223, AT1331 [patient 59], and AT1337 [patient 58]) to the AML cell lines THP-1, Molm13, MonoMac 6, and K562, and primary AML blasts freshly isolated from a patient with AML (BL-061; NPM1+). (C) AML antibodies did not bind to bone marrow–derived CD34+ hematopoietic progenitor cells, peripheral blood mononuclear cells (PBMCs), monocytes, fibroblasts, or endothelial cells isolated from healthy individuals, nor to the colon cell line HT29 or the liver cell line HepG2. Negative control: AT1002 (gray-filled histograms). HUVEC, human umbilical vein endothelial cell.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/131/1/10.1182_blood-2017-02-768762/4/blood768762f1.jpeg?Expires=1723415540&Signature=ZEkiTeBUnHI~f9BTJjJ~DuUS8av9dGle9NN1ENaNuPIKNeaDR4uWIwrNRxacht3mArGa3oW8wDajXByqkjmSuQ33NPnvbsfHO06SzEIvZ1fGKm2mlkwhxRjm4iRcSIOdSP7hFsfiAs7DvvjNJ2E5Lb9AieIaC~A3iJQhupGJRfK-rV3MG112UsA9szr2QnuoOpIBbt6cf8b2wbIumrRjdHhbheN65W3qef6OSFmfJC3jUEQogIlqk04moOWPkdo0NbhpsliK2y6OHdj~sTj4WaIyzfuGxHRkjXDu-awBWFgZ8aWOUnBbgBAK~DFKCka2Rm9h52Qh3kzJmMjREp8Weg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Identification of AML-specific antibodies. (A) Antibodies in the supernatant of 1 of the minicultures (11C9; 40 cells per well) binding to the AML cell line THP-1 (top panels). B cells from this miniculture were plated into 1 cell per well solutions and supernatants again screened for antibodies binding to THP-1 (lower panels). Positive control: HLA antigen D related (HLA-DR); negative control: in-house generated, influenza-specific antibody AT1002.12 Recombinant-produced 11C9-22C11 was named AT1223. FSC, free secretory component. (B) Representative example of binding of 3 of the selected antibodies (AT1223, AT1331 [patient 59], and AT1337 [patient 58]) to the AML cell lines THP-1, Molm13, MonoMac 6, and K562, and primary AML blasts freshly isolated from a patient with AML (BL-061; NPM1+). (C) AML antibodies did not bind to bone marrow–derived CD34+ hematopoietic progenitor cells, peripheral blood mononuclear cells (PBMCs), monocytes, fibroblasts, or endothelial cells isolated from healthy individuals, nor to the colon cell line HT29 or the liver cell line HepG2. Negative control: AT1002 (gray-filled histograms). HUVEC, human umbilical vein endothelial cell.
